PDF herunterladen
J Pediatr Infect Dis 2022; 17(06): 308-316
DOI: 10.1055/s-0042-1756713
Original Article

Serum Vitamin D Levels in Relation to Development of Multisystem Inflammatory Syndrome in Pediatric COVID-19

Neslihan Zengin 
1   Division of Pediatric Intensive Care, Department of Pediatrics, Celal Bayar University Faculty of Medicine, Manisa, Turkey
,
Alkan Bal 
2   Division of Pediatric Emergency Care, Department of Pediatrics, Celal Bayar University Faculty of Medicine, Manisa, Turkey
,
Tugba Aysun Goren 
3   Department of Pediatrics, Celal Bayar University Faculty of Medicine, Manisa, Turkey
,
Semra Sen Bayturan 
4   Division of Pediatric Infectious Diseases, Department of Pediatrics, Celal Bayar University Faculty of Medicine, Manisa, Turkey
,
Fatos Alkan 
5   Division of Pediatric Cardiology, Department of Pediatrics, Celal Bayar University Faculty of Medicine, Manisa, Turkey
,
Sinem Akcali 
6   Department of Microbiology, Celal Bayar University Faculty of Medicine, Manisa, Turkey
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Objective The aim of the study is to evaluate vitamin D (vit D) levels in children with and without development of multisystem inflammatory syndrome in children (MIS-C) after coronavirus disease 2019 (COVID-19) and also between those with severe and moderate MIS-C.

Methods This comprises retrospective data of 68 patients including 34 patients with MIS-C and admitted into the pediatric intensive care unit (MIS-C group) and 34 patients without MIS-C (non-MIS-C group) were analyzed for their presenting characteristics, serum vit D levels, ventilatory needs, and prognostic scores.

Results Vit D levels were significantly lower in patients with versus without MIS-C [9 (2–18) vs. 19 (10–43) ng/mL, p <0.001], and also in patients with severe versus moderate MIS-C [7.5 (2–17) vs. 9 (5–18) ng/mL, p = 0.024]. Vit D deficiency (levels <12 ng/mL) was more common in the MIS-C versus non-MIS-C group (79.4 vs. 11.8%, p <0.001) and in severe versus moderate MIS-C (92.9 vs. 70.0%, p <0.001). The severe versus moderate MIS-C was associated with significantly higher levels of procalcitonin [7.6 (0.9–82) vs. 1.7 (0.2–42) ng/mL, p = 0.030] and troponin [211 (4.8–4,545) vs. 14.2 (2.4–3,065) ng/L, p = 0.008] and higher likelihood of reduced ejection fraction (75.0 vs. 15.4%, p = 0.004).

Conclusion Our findings indicate the higher prevalence of vit D deficiency in pediatric COVID-19 patients with versus without MIS-C, as well as in those with severe versus moderate MIS-C. Higher troponin and procalcitonin levels and dyspnea at presentation seem also to be risk factors for severe MIS-C, more pronounced cardiac dysfunction, and poorer prognosis.

Keywords

multisystem inflammatory syndrome - pediatric COVID-19 - vitamin D - cardiac dysfunction - procalcitonin - prognostic scores


Publikationsverlauf

Eingereicht: 19. Mai 2022

Angenommen: 08. August 2022

Artikel online veröffentlicht:
04. Oktober 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Dong Y, Mo X, Hu Y. et al. Epidemiology of COVID-19 among children in China. Pediatrics 2020; 145 (06) 1-10
    CrossrefPubMedSuche in Google Scholar
  • 2 Liguoro I, Pilotto C, Bonanni M. et al. Correction to: SARS-COV-2 infection in children and newborns: a systematic review. Eur J Pediatr 2021; 180 (07) 2343
    CrossrefPubMedSuche in Google Scholar
  • 3 Sanna G, Serrau G, Bassareo PP, Neroni P, Fanos V, Marcialis MA. Children's heart and COVID-19: Up-to-date evidence in the form of a systematic review. Eur J Pediatr 2020; 179 (07) 1079-1087
    CrossrefPubMedSuche in Google Scholar
  • 4 Sperotto F, Friedman KG, Son MBF, VanderPluym CJ, Newburger JW, Dionne A. Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach. Eur J Pediatr 2021; 180 (02) 307-322
    CrossrefPubMedSuche in Google Scholar
  • 5 Deza Leon MP, Redzepi A, McGrath E. et al. COVID-19-associated pediatric multisystem inflammatory syndrome. J Pediatric Infect Dis Soc 2020; 9 (03) 407-408
    CrossrefPubMedSuche in Google Scholar
  • 6 Centers for Disease Control and Prevention. Multisystem Inflammatory Syndrome in Children (MIS-C). 2020. Accessed June 26, 2021 at: https://www.cdc.gov/mis-c/hcp/
    PubMed
  • 7 World Health Organization. Multisystem inflammatory syndrome in children and adolescents with COVID-19. 2020. Accessed May 21, 2021, at: https://www.who.int/publications/i/item/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19
    PubMed
  • 8 Henderson LA, Canna SW, Friedman KG. et al. American College of Rheumatology Clinical Guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 2. Arthritis Rheumatol 2021; 73 (04) e13-e29
    CrossrefPubMedSuche in Google Scholar
  • 9 Kabeerdoss J, Pilania RK, Karkhele R, Kumar TS, Danda D, Singh S. Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations and management. Rheumatol Int 2021; 41 (01) 19-32
    CrossrefPubMedSuche in Google Scholar
  • 10 Feketea G, Vlacha V, Bocsan IC, Vassilopoulou E, Stanciu LA, Zdrenghea M. Vitamin D in corona virus disease 2019 (COVID-19) related multisystem inflammatory syndrome in children (MIS-C). Front Immunol 2021; 12: 648546
    CrossrefPubMedSuche in Google Scholar
  • 11 Martineau AR, Jolliffe DA, Hooper RL. et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ 2017; 356: i6583
    CrossrefPubMedSuche in Google Scholar
  • 12 Yılmaz K, Şen V. Is vitamin D deficiency a risk factor for COVID-19 in children?. Pediatr Pulmonol 2020; 55 (12) 3595-3601
    CrossrefPubMedSuche in Google Scholar
  • 13 Tsabouri S, Makis A, Kosmeri C, Siomou E. Risk factors for severity in children with coronavirus disease 2019: a comprehensive literature review. Pediatr Clin North Am 2021; 68 (01) 321-338
    CrossrefPubMedSuche in Google Scholar
  • 14 Consiglio CR, Cotugno N, Sardh F. et al; CACTUS Study Team. The immunology of multisystem inflammatory syndrome in children with COVID-19. Cell 2020; 183 (04) 968-981.e7
    CrossrefPubMedSuche in Google Scholar
  • 15 Darren A, Osman M, Masilamani K. et al. Vitamin D status of children with paediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus 2 (PIMS-TS). Br J Nutr 2021; 12: 1-26
    PubMedSuche in Google Scholar
  • 16 Radia T, Williams N, Agrawal P. et al. Multi-system inflammatory syndrome in children & adolescents (MIS-C): a systematic review of clinical features and presentation. Paediatr Respir Rev 2021; 38: 51-57
    CrossrefPubMedSuche in Google Scholar
  • 17 Munns CF, Shaw N, Kiely M. et al. Global consensus recommendations on prevention and management of nutritional rickets. J Clin Endocrinol Metab 2016; 101 (02) 394-415
    CrossrefPubMedSuche in Google Scholar
  • 18 Yasuhara J, Watanabe K, Takagi H, Sumitomo N, Kuno T. COVID-19 and multisystem inflammatory syndrome in children: a systematic review and meta-analysis. Pediatr Pulmonol 2021; 56 (05) 837-848
    CrossrefPubMedSuche in Google Scholar
  • 19 Valverde I, Singh Y, Sanchez-de-Toledo J. et al; AEPC COVID-19 Rapid Response Team*. Acute cardiovascular manifestations in 286 children with multisystem inflammatory syndrome associated with COVID-19 infection in Europe. Circulation 2021; 143 (01) 21-32
    CrossrefPubMedSuche in Google Scholar
  • 20 Derespina KR, Kaushik S, Plichta A. et al. Clinical manifestations and outcomes of critically ill children and adolescents with coronavirus disease 2019 in New York City. J Pediatr 2020; 226: 55-63.e2
    CrossrefPubMedSuche in Google Scholar
  • 21 Feldstein LR, Rose EB, Horwitz SM. et al; Overcoming COVID-19 Investigators, CDC COVID-19 Response Team. Multisystem inflammatory syndrome in US Children and adolescents. N Engl J Med 2020; 383 (04) 334-346
    CrossrefPubMedSuche in Google Scholar
  • 22 Pouletty M, Borocco C, Ouldali N. et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Ann Rheum Dis 2020; 79 (08) 999-1006
    CrossrefPubMedSuche in Google Scholar
  • 23 Ahmed M, Advani S, Moreira A. et al. Multisystem inflammatory syndrome in children: a systematic review. EClinicalMedicine 2020; 26: 100527
    CrossrefPubMedSuche in Google Scholar
  • 24 Nguyen Y, Corre F, Honsel V. et al. A nomogram to predict the risk of unfavourable outcome in COVID-19: a retrospective cohort of 279 hospitalized patients in Paris area. Ann Med 2020; 52 (07) 367-375
    CrossrefPubMedSuche in Google Scholar
  • 25 Ramcharan T, Nolan O, Lai CY. et al. Paediatric inflammatory multisystem syndrome: temporally associated with SARS-CoV-2 (PIMS-TS): cardiac features, management and short-term outcomes at a UK tertiary paediatric hospital. Pediatr Cardiol 2020; 41 (07) 1391-1401
    CrossrefPubMedSuche in Google Scholar
  • 26 McCartney DM, Byrne DG. Optimisation of vitamin D status for enhanced immuno-protection against COVID-19. Ir Med J 2020; 113 (04) 58
    PubMedSuche in Google Scholar
  • 27 Kazemi A, Mohammadi V, Aghababaee SK, Golzarand M, Clark CCT, Babajafari S. Association of vitamin D status with SARS-CoV-2 infection or COVID-19 severity: a systematic review and meta-analysis. Adv Nutr 2021; 12 (05) 1636-1658
    CrossrefPubMedSuche in Google Scholar
  • 28 Stagi S, Rigante D, Lepri G, Matucci Cerinic M, Falcini F. Severe vitamin D deficiency in patients with Kawasaki disease: a potential role in the risk to develop heart vascular abnormalities?. Clin Rheumatol 2016; 35 (07) 1865-1872
    CrossrefPubMedSuche in Google Scholar
  • 29 Brown RA. Rapid response to: is ethnicity linked to incidence or outcomes of covid-19? BAME children at high risk of PIMS-TS, a Covid-19 Kawasaki-like disease - vitamin D, a factor? – testing and data urgently required. BMJ 2020; 369: 1548
    PubMedSuche in Google Scholar
  • 30 National Institute for Health and care excellence. COVID-19 Rapid Evidence Summary: Vitamin D for COVID-19 [ES28]. 2020. Accessed June 26, 2021 at: https://www.nice.org.uk/advice/es28/chapter/Key-messages
    PubMed
  • 31 Kaufman HW, Niles JK, Kroll MH, Bi C, Holick MF. SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels. PLoS One 2020; 15 (09) e0239252
    CrossrefPubMedSuche in Google Scholar